Document 3132
 DOCN  M94A3132
 TI    The prevalence of slow progressors in HIV-1 infection in Galicia, Spain.
 DT    9412
 AU    Castro A; Hermida M; Pereiro C; Lopez Calvo MS; Ruanova S; Moreno J;
       Pedreira J; Internal Medicine Service, Hospital Juan Canolejo, La
       Coruna.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):146 (abstract no. PB0011). Unique
       Identifier : AIDSLINE ICA10/94369443
 AB    ++OBJECTIVES: To analyse the prevalence of patients with slow progressor
       criteria (SP) (patients infected > 5 years and CD4 counts > 500/mm3 with
       no antirretrovirical treatment) in HIV-1 in the La Coruna area of
       500,000 inhabitants (Galicia, Northwestern Spain). METHODS: 804 HIV-1
       positive patients were studied between 1984 and 1994 in our hospital;
       581 men and 223 women with a mean age of 26.9 + 0.25 years. Risk factors
       were: 80.7% intravenous drug abusers, 5.8% heterosexual transmission,
       2.7% homo/bisexual, 0.8% post-transfussional, 10% others. Average study
       period 2.96 years (range: 30 days-10.07 years) 302 were AIDS cases.
       RESULTS: The global prevalence of SP patients was 17/804 (2.1%); 17/133
       (12.7%) in those followed for > 5 years. 12 were men and 5 women, with a
       mean age of 24.3 + 1.29 years. All of them were intravenous druf
       abusers, followed for 5.48 years (range: 5.08 + 10.07); mean CD4 cell
       count was initially 1146 + 124/mm3 and finally 1009 + 92/mm3. There were
       no epidemiological difference with non slow progressors patients.
       CONCLUSIONS: 1. The prevalence of slow progressors HIV-1 patients is low
       in Galicia. 2. All slow progressors patients were intravenous drug
       abusers. 3. CD4 cell counts remained stable in all slow progressors
       patients during follow-up.
 DE    Adult  Blood Transfusion  Female  Follow-Up Studies  Human  HIV
       Seropositivity/*EPIDEMIOLOGY/IMMUNOLOGY/*PHYSIOPATHOLOGY  Male
       Prevalence  Risk Factors  Sex Behavior  Spain/EPIDEMIOLOGY  Substance
       Abuse, Intravenous  Time Factors  T4 Lymphocytes/IMMUNOLOGY  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).